Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2010

01-05-2010 | Original Article

Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells

Authors: Jingjing Guo, Sudhakar Chintharlapalli, Syng-ook Lee, Sung Dae Cho, Ping Lei, Sabitha Papineni, Stephen Safe

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2010

Login to get access

Abstract

Purpose

1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) substituted in the phenyl ring with a para-, t-butyl, trifluoromethyl (DIM-C-pPhCF3) or phenyl (DIM-C-pPhC6H5) group activate peroxisome proliferator-activated receptor γ (PPARγ) in several cancer cell lines, and DIM-C-pPhCF3 also activates the orphan receptor Nur77. In this study, we have examined the effects of 5,5′-dihydroxy, 5,5′-dimethyl, 5,5′-dibromo, 5,5′-dinitro and 5,5′-dimethoxyindole ring-substituted analogs of DIM-C-pPhC6H5 on their activity as PPARγ agonists.

Methods

Various substituted C-DIM analogs were used to investigate their growth-inhibitory activities and activation of PPARγ-mediated transactivation in colon and pancreatic cancer cells. Their structure-dependent induction of putative PPARγ-responsive genes/proteins including p21, KLF-4 and caveolin1 were also determined by Western and Northern blot analysis.

Results

Introduction of the 5,5′-dihydroxy and 5,5′-dimethyl substituents enhanced activation of PPARγ in colon and pancreatic cancer cells. However, activation of p21 in Panc28 pancreatic cancer cells and induction of caveolin-1 and KLF4 in colon cancer cells by the C-DIM compounds were structure- and cell context-dependent.

Conclusions

The results demonstrate that DIM-C-pPhC6H5 and indole ring-substituted analogs are selective PPARγ modulators.
Literature
1.
go back to reference Hong J, Samudio I, Liu S, Abdelrahim M, Safe S (2004) Peroxisome proliferator-activated receptor γ-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 145:5774–5785CrossRefPubMed Hong J, Samudio I, Liu S, Abdelrahim M, Safe S (2004) Peroxisome proliferator-activated receptor γ-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 145:5774–5785CrossRefPubMed
2.
go back to reference Vanderlaag K, Su Y, Frankel AE, Grage H, Smith R III, Khan S, Safe S (2008) 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res Treat 109:273–283CrossRefPubMed Vanderlaag K, Su Y, Frankel AE, Grage H, Smith R III, Khan S, Safe S (2008) 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res Treat 109:273–283CrossRefPubMed
3.
go back to reference Chintharlapalli S, Smith R III, Samudio I, Zhang W, Safe S (2004) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation and differentiation markers in colon cancer cells. Cancer Res 64:5994–6001CrossRefPubMed Chintharlapalli S, Smith R III, Samudio I, Zhang W, Safe S (2004) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation and differentiation markers in colon cancer cells. Cancer Res 64:5994–6001CrossRefPubMed
4.
go back to reference Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S (2005) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and NAG-1. Mol Pharmacol 68:1782–1792PubMed Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S (2005) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and NAG-1. Mol Pharmacol 68:1782–1792PubMed
5.
go back to reference Chintharlapalli S, Papineni S, Safe S (2006) 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways. Mol Cancer Ther 5:1362–1370CrossRefPubMed Chintharlapalli S, Papineni S, Safe S (2006) 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways. Mol Cancer Ther 5:1362–1370CrossRefPubMed
6.
go back to reference Chintharlapalli S, Papineni S, Safe SH (2007) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through PPARγ-independent pathways. Mol Pharmacol 71:558–569CrossRefPubMed Chintharlapalli S, Papineni S, Safe SH (2007) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through PPARγ-independent pathways. Mol Pharmacol 71:558–569CrossRefPubMed
7.
go back to reference Contractor R, Samudio I, Estrov Z, Harris D, McCubrey JA, Safe S, Andreeff M, Konopleva M (2005) A novel ring-substituted diindolylmethane 1,1-bis[3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl)methane inhibits ERK activation and induces apoptosis in acute myeloid leukemia. Cancer Res 65:2890–2898CrossRefPubMed Contractor R, Samudio I, Estrov Z, Harris D, McCubrey JA, Safe S, Andreeff M, Konopleva M (2005) A novel ring-substituted diindolylmethane 1,1-bis[3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl)methane inhibits ERK activation and induces apoptosis in acute myeloid leukemia. Cancer Res 65:2890–2898CrossRefPubMed
8.
go back to reference Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith R III, Phillips T, Abdelrahim M, Samudio I, Safe S (2004) A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes. Mol Cancer Therap 3:247–259 Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith R III, Phillips T, Abdelrahim M, Samudio I, Safe S (2004) A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes. Mol Cancer Therap 3:247–259
9.
go back to reference Vanderlaag K, Samudio I, Burghardt R, Barhoumi R, Safe S (2005) Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3′-indolyl)methane (DIM) and 5,5′-dibromoDIM. Cancer Lett 236:198–212CrossRefPubMed Vanderlaag K, Samudio I, Burghardt R, Barhoumi R, Safe S (2005) Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3′-indolyl)methane (DIM) and 5,5′-dibromoDIM. Cancer Lett 236:198–212CrossRefPubMed
10.
go back to reference York M, Abdelrahim M, Chintharlapalli S, Lucero SD, Safe S (2007) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clin Cancer Res 13:6743–6752CrossRefPubMed York M, Abdelrahim M, Chintharlapalli S, Lucero SD, Safe S (2007) 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clin Cancer Res 13:6743–6752CrossRefPubMed
11.
go back to reference Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S (2006) 3,3′-Diindolylmethane (DIM) and derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27:717–728CrossRefPubMed Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S (2006) 3,3′-Diindolylmethane (DIM) and derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27:717–728CrossRefPubMed
12.
go back to reference Calabro P, Samudio I, Safe SH, Willerson JT, Yeh ET (2005) Inhibition of tumor necrosis factor-α-induced endothelial cell activation by a new class of PPARγ agonists: an in vitro study. J Vascular Res 42:509–516CrossRef Calabro P, Samudio I, Safe SH, Willerson JT, Yeh ET (2005) Inhibition of tumor necrosis factor-α-induced endothelial cell activation by a new class of PPARγ agonists: an in vitro study. J Vascular Res 42:509–516CrossRef
13.
go back to reference Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM (2006) Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res 66:412–418CrossRefPubMed Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM (2006) Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res 66:412–418CrossRefPubMed
14.
go back to reference Lei P, Abdelrahim M, Safe S (2006) 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol Cancer Ther 5:2324–2336CrossRefPubMed Lei P, Abdelrahim M, Safe S (2006) 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol Cancer Ther 5:2324–2336CrossRefPubMed
15.
go back to reference Cho SD, Yoon K, Chintharlapalli S, Abdelrahim M, Pei P, Hamilton S, Khan S, Ramaiah SK, Safe S (2007) Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and independent pathways. Cancer Res 67:674–683CrossRefPubMed Cho SD, Yoon K, Chintharlapalli S, Abdelrahim M, Pei P, Hamilton S, Khan S, Ramaiah SK, Safe S (2007) Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and independent pathways. Cancer Res 67:674–683CrossRefPubMed
16.
go back to reference Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S (2007) Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ (PPARγ) agonists in colon cancer cells. Mol Cancer Therap 6:1588–1598CrossRef Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S (2007) Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ (PPARγ) agonists in colon cancer cells. Mol Cancer Therap 6:1588–1598CrossRef
17.
go back to reference Chen ZY, Tseng CC (2005) 15-Deoxy-Δ12, 14 prostaglandin J2 up-regulates Krüppel-like factor 4 expression independently of peroxisome proliferator-activated receptor γ by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol Pharmacol 68:1203–1213CrossRefPubMed Chen ZY, Tseng CC (2005) 15-Deoxy-Δ12, 14 prostaglandin J2 up-regulates Krüppel-like factor 4 expression independently of peroxisome proliferator-activated receptor γ by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol Pharmacol 68:1203–1213CrossRefPubMed
18.
go back to reference Escher P, Wahli W (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448:121–138PubMed Escher P, Wahli W (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448:121–138PubMed
19.
go back to reference Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1–9CrossRefPubMed Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1–9CrossRefPubMed
20.
go back to reference Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB (1999) A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 59:336–341PubMed Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB (1999) A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 59:336–341PubMed
21.
go back to reference Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W (2002) A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628–2644CrossRefPubMed Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W (2002) A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628–2644CrossRefPubMed
22.
go back to reference Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 17:662–676CrossRefPubMed Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 17:662–676CrossRefPubMed
23.
go back to reference Koyama H, Miller DJ, Boueres JK, Desai RC, Jones AB, Berger JP, Macnaul KL, Kelly LJ, Doebber TW, Wu MS, Zhou G, Wang PR, Ippolito MC, Chao YS, Agrawal AK, Franklin R, Heck JV, Wright SD, Moller DE, Sahoo SP (2004) (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents. J Med Chem 47:3255–3263CrossRefPubMed Koyama H, Miller DJ, Boueres JK, Desai RC, Jones AB, Berger JP, Macnaul KL, Kelly LJ, Doebber TW, Wu MS, Zhou G, Wang PR, Ippolito MC, Chao YS, Agrawal AK, Franklin R, Heck JV, Wright SD, Moller DE, Sahoo SP (2004) (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents. J Med Chem 47:3255–3263CrossRefPubMed
24.
go back to reference Acton JJ III, Black RM, Jones AB, Moller DE, Colwell L, Doebber TW, Macnaul KL, Berger J, Wood HB (2005) Benzoyl 2-methyl indoles as selective PPARγ modulators. Bioorg Med Chem Lett 15:357–362CrossRefPubMed Acton JJ III, Black RM, Jones AB, Moller DE, Colwell L, Doebber TW, Macnaul KL, Berger J, Wood HB (2005) Benzoyl 2-methyl indoles as selective PPARγ modulators. Bioorg Med Chem Lett 15:357–362CrossRefPubMed
25.
go back to reference Liu K, Black RM, Acton JJ III, Mosley R, Debenham S, Abola R, Yang M, Tschirret-Guth R, Colwell L, Liu C, Wu M, Wang CF, Macnaul KL, McCann ME, Moller DE, Berger JP, Meinke PT, Jones AB, Wood HB (2005) Selective PPARγ modulators with improved pharmacological profiles. Bioorg Med Chem Lett 15:2437–2440CrossRefPubMed Liu K, Black RM, Acton JJ III, Mosley R, Debenham S, Abola R, Yang M, Tschirret-Guth R, Colwell L, Liu C, Wu M, Wang CF, Macnaul KL, McCann ME, Moller DE, Berger JP, Meinke PT, Jones AB, Wood HB (2005) Selective PPARγ modulators with improved pharmacological profiles. Bioorg Med Chem Lett 15:2437–2440CrossRefPubMed
26.
go back to reference Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA (2005) Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc Natl Acad Sci USA 102:2340–2345CrossRefPubMed Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA (2005) Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc Natl Acad Sci USA 102:2340–2345CrossRefPubMed
27.
go back to reference Baek SJ, Wilson LC, Hsi LC, Eling TE (2003) Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278:5845–5853CrossRefPubMed Baek SJ, Wilson LC, Hsi LC, Eling TE (2003) Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278:5845–5853CrossRefPubMed
28.
go back to reference Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE (2004) Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 279:6883–6892CrossRefPubMed Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE (2004) Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 279:6883–6892CrossRefPubMed
29.
go back to reference Chintharlapalli S, Papineni S, Liu S, Jutooru I, Chadalapaka G, Cho SD, Murthy R, You YJ, Safe S (2007) 2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor γ in colon and pancreatic cancer cells. Carcinogenesis 28:2337–2346CrossRefPubMed Chintharlapalli S, Papineni S, Liu S, Jutooru I, Chadalapaka G, Cho SD, Murthy R, You YJ, Safe S (2007) 2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor γ in colon and pancreatic cancer cells. Carcinogenesis 28:2337–2346CrossRefPubMed
Metadata
Title
Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells
Authors
Jingjing Guo
Sudhakar Chintharlapalli
Syng-ook Lee
Sung Dae Cho
Ping Lei
Sabitha Papineni
Stephen Safe
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1144-0

Other articles of this Issue 1/2010

Cancer Chemotherapy and Pharmacology 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine